Study wrapper · #1237
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.
Editor's note
This is observational target-trial emulation, not a randomized head-to-head, so residual confounding remains possible despite propensity matching. The sitagliptin benchmark is the useful detail: it shows the design had enough resolution to separate incretin users from a weaker comparator, and against that backdrop tirzepatide and semaglutide were indistinguishable on hard liver endpoints. Read the extra BMI reduction with tirzepatide as decoupled from liver outcomes over this window rather than as a signal of hepatic advantage. Seventeen months is short for cirrhosis progression, so the comparison stays open.
Plain-language abstract
This retrospective analysis used the TriNetX global health-record network to compare adults with type 2 diabetes and overweight or obesity who started tirzepatide against those who started injectable semaglutide, then followed both groups for serious liver events - cirrhosis, decompensation, or liver cancer. After matching the groups on baseline characteristics, rates over a median of about 17 months were nearly identical, roughly 4 events per 1,000 person-years in each group, with a hazard ratio of 1.04. The same pattern held among people with MASLD and in an analysis restricted to time on drug. Tirzepatide produced about 1.1 kg/m2 more BMI reduction, and both drugs showed fewer liver events than sitagliptin, the internal benchmark the authors used to confirm their method could detect a real difference.